Press release
Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn’s and Colitis Organisation
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data related to GB004 at the 2021 Virtual Congress of the European Crohn’s and Colitis Organisation (ECCO), to be held virtually from July 2-3 and 8-10. On July 8, William Sandborn, M.D., will present a digital oral presentation, which will include target engagement and pharmacodynamic biomarker data from the completed GB004 Phase 1b clinical trial in patients with mild-to-moderate ulcerative colitis.\n\nDetails for presentations related to GB004, an oral, gut-target HIF-1α stabilizer, are as follows:\n\nDigital Oral Presentation Title: Target Engagement and Pharmacodynamic Biomarker Analysis following Treatment with the Oral Gut-Targeted HIF-1α Stabilizer GB004 in a Phase 1b Trial in Active Ulcerative Colitis\nPresenting Author: William Sandborn, M.D.\nDate: Thursday, July 8, 2021\nSession Title: DOP Session 1 - Molecular Profiling\nPresentation Code: DOP05\nPresentation Time: 8:10 – 8:15 a.m. PDT / 11:10 – 11:15 a.m. EDT / 5:10 – 5:15 p.m. CEST\n\nePoster Title: GB004 Drives Protective Effects on Immune Cells and Epithelial Cells Using Human Ex Vivo Monolayer and Co-Culture Systems\nPoster Code: P059\n\nThe presentation and poster can be accessed on the ECCO website. The presentation and poster will also be made available in the “Posters and Publications” section of the Gossamer Bio website at gossamerbio.com, after the conclusion of the Virtual Congress.\n\nAbout Gossamer Bio\n\nGossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210707005256/en/\n\nFor Investors and Media:\nBryan Giraudo, Chief Financial Officer\nGossamer Bio Investor Relations\[email protected]\n\nSource: Gossamer Bio, Inc.","length":4132,"tagName":"div"}]